Therapeutic impact and routine application of next‑generation sequencing: A single institute study

Hernández‑Pacheco Acosta,Rocío; Del Carmen Damas Fuentes,María; Gallego Pena,Nicolás; Soto Rojas,Pilar; Beato Zambrano,Carmen

doi:10.3892/br.2022.1516

Therapeutic impact and routine application of next‑generation sequencing: A single institute study

Authors:
- Rocío Hernández‑Pacheco Acosta
- María Del Carmen Damas Fuentes
- Nicolás Gallego Pena
- Pilar Soto Rojas
- Carmen Beato Zambrano
View Affiliations

Affiliations: Department of Medical Oncology, Virgen Macarena University Hospital, 41009 Seville, Spain
Published online on: March 1, 2022 https://doi.org/10.3892/br.2022.1516
Article Number: 33
Copyright: © Hernández‑Pacheco Acosta et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Genomic sequencing of tumor tissues provides information on actionable gene aberrations that have diagnostic and therapeutic significance and may guide clinical management through the use of targeted therapies. The indications for these techniques and their possible limitations for application in daily practice should be established as a priority. In the present study, a group of patients with few suitable therapeutic options who were eligible for a next‑generation sequencing (NGS) analysis were analyzed, and the molecular targets identified and their therapeutic impact are described. A series of 26 patients treated at the Virgen Macarena Hospital for whom an NGS study was requested between January 2017 and December 2019 were reviewed. Actionable molecular alterations were identified in 20 of the cases, and 4 patients received NGS‑guided treatment. NGS techniques represent a novel opportunity for guiding treatment in cancer patients. Patients with few therapeutic alternatives, either due to diagnosis, atypical evolution or resistance to standard therapy, may be suitable candidates.

View Figures

View References

1	Jameson JL and Longo DL: Precision medicine-personalized, problematic, and promising. N Engl J Med. 372:2229–2234. 2015.PubMed/NCBI View Article : Google Scholar
2	Jordan VC: Fourteenth gaddum memorial lecture. A current view of tamoxifen for the treatment and prevention of breast cancer. Br J Pharmacol. 110:507–517. 1993.PubMed/NCBI View Article : Google Scholar
3	Buchdunger E, Zimmermann J, Mett H, Meyer T, Müller M, Druker BJ and Lydon NB: Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56:100–104. 1996.PubMed/NCBI
4	Andre F, Mardis E, Salm M, Soria JC, Siu LL and Swanton C: Prioritizing targets for precision cancer medicine. Ann Oncol. 25:2295–2303. 2014.PubMed/NCBI View Article : Google Scholar
5	Maxam MA and Gilbert W: A new method for sequencing DNA. Proc Natl Acad Sci USA. 74:560–564. 1977.PubMed/NCBI View Article : Google Scholar
6	Heather JM and Chain B: The sequence of sequencers: The history of sequencing DNA. Genomics. 107:1–8. 2016.PubMed/NCBI View Article : Google Scholar
7	Mardis ER: Next-generation DNA sequencing methods. Annu Rev Genomics Hum Genet. 9:387–402. 2008.PubMed/NCBI View Article : Google Scholar
8	Shendure J and Ji H: Next-generation DNA sequencing. Nat Biotechnol. 26:1135–1145. 2008.PubMed/NCBI View Article : Google Scholar
9	Behjati S and Tarpey PS: What is next generation sequencing? Arch Dis Child Educ Pract Ed. 98:236–238. 2013.PubMed/NCBI View Article : Google Scholar
10	Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried M, Penel N, Hansen AR, et al: Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study. J Clin Oncol. 38:1–10. 2020.PubMed/NCBI View Article : Google Scholar
11	Looney AM, Nawaz K and Webster RM: Tumour-agnostic therapies. Nat Rev Drug Discov. 19:383–384. 2020.PubMed/NCBI View Article : Google Scholar
12	Park JJH, Hsu G, Siden EG, Thorlund K and Mills EJ: An overview of precision oncology basket and umbrella trials for clinicians. CA Cancer J Clin. 70:125–137. 2020.PubMed/NCBI View Article : Google Scholar
13	Goodwin S, McPherson JD and McCombie WR: Coming of age: Ten years of next-generation sequencing technologies. Nat Rev Genet. 17:333–351. 2016.PubMed/NCBI View Article : Google Scholar
14	Liu Z, Zhu L, Roberts R and Tong W: Toward clinical implementation of next-generation sequencing-based genetic testing in rare diseases: Where are we? Trends Genet. 35:852–867. 2019.PubMed/NCBI View Article : Google Scholar
15	Gatta G, Capocaccia R, Botta L, Mallone S, De Angelis R, Ardanaz E, Comber H, Dimitrova N, Leinonen MK, Siesling S, et al: Burden and centralised treatment in Europe of rare tumours: Results of RARECAREnet-a population-based study. Lancet Oncol. 18:1022–1039. 2017.PubMed/NCBI View Article : Google Scholar
16	Subbiah IM, Tsimberidou A, Subbiah V, Janku F, Roy-Chowdhuri S and Hong DS: Next generation sequencing of carcinoma of unknown primary reveals novel combinatorial strategies in a heterogeneous mutational landscape. Oncoscience. 4:47–56. 2017.PubMed/NCBI View Article : Google Scholar
17	Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, Schnall-Levin M, White J, Sanford EM, An P, et al: Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 31:1023–1031. 2013.PubMed/NCBI View Article : Google Scholar
18	Alegretti M, Fabi A, Buglioni S, Martayan A, Conti L, Pescarmona E, Ciliberto G and Giacomini P: Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations. J Exp Clin Cancer Res. 37(47)2018.PubMed/NCBI View Article : Google Scholar
19	Matthijs G, Souche E, Alders M, Corveleyn A, Eck S, Feenstra I, Race V, Sistermans E, Sturm M, Weiss M, et al: Guidelines for diagnostic next-generation sequencing. Eur J Hum Genet. 24(1515)2016.PubMed/NCBI View Article : Google Scholar
20	Marquart J, Chen EY and Prasad V: Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology. JAMA Oncol. 4:1093–1098. 2018.PubMed/NCBI View Article : Google Scholar
21	Schwartzberg L, Kim ES, Liu D and Schrag D: Precision oncology: Who, how, what, when, and when not? Am Soc Clin Oncol Educ Book. 37:160–169. 2017.PubMed/NCBI View Article : Google Scholar
22	Colomer R, Mondejar R, Romero-Laorden N, Alfranca A, Sanchez-Madrid F and Quintela-Fandino M: When should we order a next generation sequencing test in a patient with cancer? EClinicalMedicine. 25(100487)2020.PubMed/NCBI View Article : Google Scholar
23	Binder C, Matthes KL, Korol D, Rohrmann S and Moch H: Cancer of unknown primary-Epidemiological trends and relevance of comprehensive genomic profiling. Cancer Med. 7:4814–4824. 2018.PubMed/NCBI View Article : Google Scholar
24	Subbiah V, Solit DB, Chan TA and Kurzrock R: The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: A decision centered on empowering patients and their physicians. Ann Oncol. 31:1115–1118. 2020.PubMed/NCBI View Article : Google Scholar
25	Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, Chung HC, Kindler HL, Lopez-Martin JA, Miller WH Jr, et al: Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: Prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 21:1353–1365. 2020.PubMed/NCBI View Article : Google Scholar
26	Sunami K, Ichikawa H, Kubo T, Kato M, Fujiwara Y, Shimomura A, Koyama T, Kakishima H, Kitami M, Matsushita H, et al: Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study. Cancer Sci. 110:1480–1490. 2019.PubMed/NCBI View Article : Google Scholar
27	Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, Normanno N, Scarpa A, Robson M, Meric-Bernstam F, et al: Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO precision medicine working group. Ann Oncol. 31:1491–1505. 2020.PubMed/NCBI View Article : Google Scholar
28	Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N, Ng CKY, Bedard PL, Tortora G, Douillard JY, et al: A framework to rank genomic alterations as targets for cancer precision medicine: The ESMO scale for clinical actionability of molecular targets (ESCAT). Ann Oncol. 29:1895–1902. 2018.PubMed/NCBI View Article : Google Scholar
29	Hotta K, Aoe K, Kozuki T, Ohashi K, Ninomiya K, Ichihara E, Kubo T, Ninomiya T, Chikamori K, Harada D, et al: A phase II study of trastuzumab emtansine in HER2-positive non-small cell lung cancer. J Thorac Oncol. 13:273–279. 2018.PubMed/NCBI View Article : Google Scholar